首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1724825

流感疫苗市場規模、佔有率、成長分析（按類型、適應症、技術、給藥途徑、年齡層、分銷管道和地區）—2025 年至 2032 年產業預測

Influenza Vaccine Market Size, Share, and Growth Analysis, By Type, By Indication, By Technology, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年05月07日 | 出版商:

SkyQuest | 英文 200 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球流感疫苗市場價值為 79 億美元，預計將從 2024 年的 84.4 億美元成長到 2032 年的 142.8 億美元，預測期內（2025-2032 年）的複合年成長率為 6.8%。

流感病毒仍然是持續的健康威脅，造成局部流行病和大量死亡。僅在 2019-20 年流感季節，美國疾病管制與預防中心就報告了超過 1,300 萬例流感病例。由於病毒不斷進化，每年調整疫苗株以達到最佳效果至關重要。隨著流感疫情持續上升，疫苗需求的成長預計將推動市場銷售。目前，多種季節性流感疫苗已獲得世界衛生組織（WHO）和美國疾病管制與預防中心（CDC）的核准，世界各國政府都優先接種疫苗，以在流感季節最大限度地保護本國公民。製藥業在疫苗開發方面面臨持續的挑戰，進一步增加了市場對創新有效流感疫苗的需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Sanofi Pasteur（France）
GlaxoSmithKline plc（GSK）（United Kingdom）
Seqirus（a CSL Limited Company）（Australia）
Pfizer Inc.（United States）
AstraZeneca PLC（United Kingdom）
Novavax, Inc.（United States）
Bharat Biotech（India）
Johnson & Johnson（United States）
MedImmune, LLC（AstraZeneca）（United States）
FluGen（United States）
Emergent BioSolutions（United States）
Sinovac Biotech Ltd.（China）
Bio Farma（Indonesia）
Serum Institute of India Pvt. Ltd.（India）
Abbott Biologicals BV（Netherlands）
Adimmune Corporation（Taiwan）
BIKEN Co., Ltd.（Japan）
Changchun BCHT Biotechnology Co.（China）

結論和建議

簡介目錄

Product Code: SQMIG35B2144

Global Influenza Vaccine Market size was valued at USD 7.9 billion in 2023 and is poised to grow from USD 8.44 billion in 2024 to USD 14.28 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The influenza virus remains a persistent health threat, causing regional epidemics and leading to significant mortality. In the 2019-20 season alone, the Centers for Disease Control and Prevention reported over 13 million flu cases. Due to the virus's evolving nature, annual adjustments to vaccine strains are essential for optimal effectiveness. As influenza outbreaks continue to increase, a growing demand for vaccines is anticipated to drive market sales. Currently, various licensed seasonal influenza vaccines are endorsed by the World Health Organization and CDC to combat the virus, with governments emphasizing vaccination to maximize public protection during flu seasons. The pharmaceutical sector faces ongoing challenges in vaccine development, further heightening the demand for innovative and effective influenza vaccines in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Vaccine Market Segments Analysis

Global Influenza Vaccine Market is segmented by Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel and region. Based on Type, the market is segmented into Inactivated and Live Attenuated. Based on Indication, the market is segmented into Quadrivalent and Trivalent. Based on Technology, the market is segmented into Egg-based and Cell-based. Based on Route of Administration, the market is segmented into Injection and Nasal Spray. Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Vaccine Market

Government support and enhanced surveillance for influenza vaccinations are pivotal drivers of the global influenza vaccine market. Effective monitoring at both national and international levels is essential to oversee the supply, distribution, and administration of flu vaccines. Organizations like the World Health Organization (WHO) collaborate with various governments to assess demand and implement immunization programs aimed at reducing regional vaccine requirements. For example, in 2021, the Australian government successfully vaccinated around 5 million individuals through its immunization initiatives, with over 20 million doses still available for further distribution. This ongoing commitment underscores the essential role of government intervention in stimulating vaccine uptake.

Restraints in the Global Influenza Vaccine Market

The global influenza vaccine market faces significant restraints primarily due to the lengthy and complex nature of vaccine development, which typically spans 10 to 15 years. This protracted timeline is influenced by several factors, including the intricacies involved in creating vaccines, the need for global clinical trials, and the variations in regulatory requirements across different regions. These regulatory variations can result in considerable delays as countries often have distinct labeling mandates and compressed timelines for clinical trials. The cumulative effect of stringent regulations and extended development periods is expected to hinder the progress of novel influenza vaccine products in the market.

Market Trends of the Global Influenza Vaccine Market

The Global Influenza Vaccine market is experiencing a notable upward trend, propelled by the heightened awareness surrounding immunization following the coronavirus pandemic. As health experts and government health departments amplify their advocacy for flu vaccinations, more individuals are opting for these preventive measures, leading to a surge in vaccination rates in both developing and developed countries. Additionally, the extension and expansion of government programs offering free flu vaccinations have further incentivized uptake. This evolving landscape underscores a growing emphasis on public health initiatives, thereby driving an increase in market demand and fostering opportunities for vaccine manufacturers and healthcare providers alike.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technology Analysis

Global Influenza Vaccine Market Size by Type & CAGR (2025-2032)

Market Overview
Inactivated
Live Attenuated

Global Influenza Vaccine Market Size by Indication & CAGR (2025-2032)

Market Overview
Quadrivalent
Trivalent

Global Influenza Vaccine Market Size by Technology & CAGR (2025-2032)

Market Overview
Egg-based
Cell-based

Global Influenza Vaccine Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Injection
Nasal Spray

Global Influenza Vaccine Market Size by Age Group & CAGR (2025-2032)

Market Overview
Pediatric
Adult

Global Influenza Vaccine Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital & Pharmacies
Government & Institutional Supply
Other

Global Influenza Vaccine Market Size & CAGR (2025-2032)

North America (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
- US
- Canada
Europe (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Sanofi Pasteur (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seqirus (a CSL Limited Company) (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MedImmune, LLC (AstraZeneca) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FluGen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Farma (Indonesia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Biologicals B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adimmune Corporation (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BIKEN Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Changchun BCHT Biotechnology Co. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments